Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.8 |
mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |